[Congressional Bills 108th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5429 Introduced in House (IH)]






108th CONGRESS
  2d Session
                                H. R. 5429

   To require the National Institute on Drug Abuse to develop a meta-
  analysis of the available scientific data regarding the safety and 
      health risks of smoking marijuana and the clinically-proven 
   effectiveness of smoking marijuana for medicinal purposes, and to 
 require the Food and Drug Administration to promptly disseminate the 
                             meta-analysis.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                            December 6, 2004

 Mr. Souder (for himself, Mr. Kingston, Mr. Sessions, Mr. Smith of New 
   Jersey, and Mr. Bonilla) introduced the following bill; which was 
            referred to the Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL


 
   To require the National Institute on Drug Abuse to develop a meta-
  analysis of the available scientific data regarding the safety and 
      health risks of smoking marijuana and the clinically-proven 
   effectiveness of smoking marijuana for medicinal purposes, and to 
 require the Food and Drug Administration to promptly disseminate the 
                             meta-analysis.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Safe and Effective Drug Act''.

SEC. 2. SAFETY AND EFFECTIVENESS OF SMOKING MARIJUANA FOR MEDICINAL 
              PURPOSES; META-ANALYSIS BY NATIONAL INSTITUTE ON DRUG 
              ABUSE.

    (a) In General.--The Director of the National Institutes of Health, 
acting through the Director of the National Institute on Drug Abuse 
(referred to in this Act as the ``Director of the Institute''), shall 
develop a meta-analysis of the available scientific data regarding the 
safety and health risks of smoking marijuana and the clinically-proven 
effectiveness of smoking marijuana for medicinal purposes.
    (b) Completion of Meta-Analysis; Report.--Not later than 120 days 
after the date of the enactment of this Act, the Director of the 
Institute shall complete the meta-analysis under subsection (a) and 
submit to the Congress a report providing the meta-analysis. The 
Director shall transmit a copy of the report to the Commissioner of 
Food and Drugs.

SEC. 3. DISSEMINATION OF META-ANALYSIS BY FOOD AND DRUG ADMINISTRATION.

    (a) Public Access to Meta-Analysis Through Internet.--Not later 
than 30 days after receiving from the Director of the Institute the 
report under section 2(b), the Commissioner of Food and Drugs shall 
post such report on the Internet site of the Food and Drug 
Administration.
    (b) Dissemination of Meta-Analysis to Certain Public Health 
Agencies and Other Appropriate Entities.--Promptly after receiving from 
the Director of the Institute the report under section 2(b), the 
Commissioner of Food and Drugs shall disseminate the report--
            (1) to principal public health agencies of all States, 
        including those that authorize the smoking of marijuana for 
        medicinal purposes; and
            (2) to public health associations, health care 
        professionals, and other appropriate entities that advocate or 
        recommend the smoking of marijuana by patients for medicinal 
        purposes.
    (c) Definition.--As used in this section, the term ``State'' means 
each of the several States, the District of Columbia, the Commonwealth 
of Puerto Rico, the Commonwealth of the Northern Mariana Islands, 
American Samoa, Guam, the Virgin Islands, and any other territory or 
possession of the United States.
                                 <all>